PolyMedix Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria – MarketWatchPosted: January 20, 2012
At the same scientific meeting, Dr. Doron Greenbaum, Assistant Professor of Pharmacology at the University of Pennsylvania, presented in vitro and in vivo data showing that PolyMedixs antimicrobial compounds show promising activity in experimental models of malaria. The data presented showed that PolyMedixs antimicrobial compounds potently killed the parasite that causes malaria, Plasmodium falciparum, in infected human red blood cells, without damaging uninfected red blood cells. The compounds appear to rapidly target the membrane of the digestive vacuole of the parasite via a unique mechanism which is distinct from other anti-malarial agents. Encouraging in vivo activity was also reported with a potential lead compound on malaria parasite clearance and animal survival in a mouse malaria model. This work was supported under a Fast Track SBIR grant received from the National Institute of Health NIH.